Haemonetics (HAE) Tops Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $127.42 --0%
Financial Fact:
Operating income: 24.79M
Today's EPS Names:
SENEA, XFOR, MG, More
Financial Fact:
Operating income: 24.79M
Today's EPS Names:
SENEA, XFOR, MG, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q2 EPS of $1.35, $0.06 better than the analyst estimate of $1.29. Revenue for the quarter came in at $358 million versus the consensus estimate of $345.15 million.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ACM Research (ACMR) Tops Q3 EPS by 6c ; Offers Guidance
- Mineralys Therapeutics, Inc. (MLYS) Tops Q3 EPS by 11c
- Damora Therapeutics, Inc. (DMRA) Tops Q3 EPS by 8c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
